Subject(s)
Meningomyelocele/complications , Meningomyelocele/therapy , Trisomy 18 Syndrome/complications , Anti-Bacterial Agents/therapeutic use , Fatal Outcome , Female , Humans , Hypertension, Pulmonary/complications , Infant, Extremely Low Birth Weight , Infant, Newborn , Male , Polyhydramnios/diagnosis , Pregnancy , Prenatal Diagnosis , Respiration, Artificial/methodsSubject(s)
Chondrodysplasia Punctata , Peroxisomal Disorders , Zellweger Syndrome , Hip Joint , Humans , RadiographyABSTRACT
Transient neonatal hyperparathyroidism (TNHP) is etiologically a heterogeneous condition. One of the etiologies is an insufficient maternal-fetal calcium transport through the placenta. We report six subjects with homozygous and/or compound-heterozygous mutations in the gene encoding the transient receptor potential cation channel, subfamily V, member 6 (TRPV6), an epithelial Ca2+-selective channel associated with this condition. Exome sequencing on two neonates with skeletal findings consistent with neonatal hyperparathyroidism identified homozygous frameshift mutations before the first transmembrane domain in a subject born to first-cousins parents of Pakistani descent as well as compound-heterozygous mutations (a combination of a frameshift mutation and an intronic mutation that alters mRNA splicing) in an individual born to a non-consanguineous couple of African descent. Subsequently, targeted mutation analysis of TRPV6 performed on four other individuals (born to non-consanguineous Japanese parents) with similar X-rays findings identified compound-heterozygous mutations. The skeletal findings improved or resolved in most subjects during the first few months of life. We identified three missense variants (at the outer edges of the second and third transmembrane domains) that alter the localization of the TRPV6: one recurrent variant at the S2-S3 loop and two recurrent variants (in the fourth ankyrin repeat domain) that impair TRPV6 stability. Compound heterozygous loss-of-function mutations for the pathogenic frameshift allele and the allele with an intronic c.607+5G>A mutation resulted in the most severe phenotype. These results suggest that TNHP is an autosomal-recessive disease caused by TRPV6 mutations that affect maternal-fetal calcium transport.
Subject(s)
Calcium Channels/genetics , Calcium/metabolism , Fetus/metabolism , Hyperparathyroidism/genetics , Maternal-Fetal Exchange , Mutation/genetics , Placenta/metabolism , TRPV Cation Channels/genetics , Adult , Base Sequence , Female , HEK293 Cells , Humans , Hyperparathyroidism/blood , Hyperparathyroidism/diagnostic imaging , Infant, Newborn , Ion Transport , Male , Pedigree , PregnancyABSTRACT
BACKGROUND: Preterm infants are at significant risk of reduced bone mineral content and subsequent bone disease (metabolic bone disease of prematurity, MBDP). MBDP is frequently found in very low-birthweight (VLBW) infants, but long-term height prognosis is not well known. METHODS: VLBW infants from two major neonatal intensive care units were studied. Medical records were reviewed. A total of 143 subjects were analyzed after excluding subjects who died, or who had severe complications that could affect linear growth, Silver-Russell syndrome, severe cholestasis, and/or chromosomal abnormality. The relationship between MBDP and height at age 3 was investigated. RESULTS: Height standard deviation score (SDS) at age 3 negatively correlated with peak serum alkaline phosphatase (ALP) activity in early life (r = -0.30, P = 0.0003) and positively correlated with serum phosphorus (P) at peak ALP (r = 0.33, P = 0.0002). In addition, serum P independently affected height SDS at 3 years of age (ß = 0.19, P = 0.018), and was significantly different between infants with and without catch-up growth in height (difference: 0.23 mmol/L, 95%CI: 0.09-0.36, P = 0.0010). CONCLUSIONS: MBDP, particularly hypophosphatemia in the early period of life, is associated with linear growth until 3 years of age in VLBW infants.
Subject(s)
Bone Density/physiology , Bone Diseases, Metabolic/metabolism , Bone and Bones/metabolism , Infant, Premature, Diseases/epidemiology , Infant, Premature , Infant, Very Low Birth Weight , Minerals/metabolism , Bone Diseases, Metabolic/diagnosis , Child, Preschool , Disease Progression , Female , Gestational Age , Humans , Infant , Infant, Newborn , Infant, Premature, Diseases/metabolism , Male , PrognosisABSTRACT
OBJECTIVE: Our objective was to evaluate effects of levothyroxine (l-T4) supplementation against neurodevelopmental outcomes at 18 months of corrected age in very-low-birth-weight (VLBW) infants with hypothyroxinemia but without elevated thyroid-stimulating hormone (TSH) concentration. METHODS: VLBW infants who had plasma TSH concentrations <10 µU/mL and free thyroxine (FT4) concentrations <0.8 ng/dL between 2 and 4 weeks of age were enrolled. They were randomly assigned to either the Treated (n=25) or Untreated group (n=45). The Treated group received l-T4 at a dose of 5 µg/kg/day. We compared growth and neurodevelopmental outcomes at 18 months of corrected age in the two groups. RESULTS: There were no significant differences in growth, the incidences of developmental delay, cerebral palsy, visual impairment, and hearing impairment in the two groups. CONCLUSIONS: In such infants, l-T4 supplementation at a dose of 5 µg/kg/day did not affect FT4 levels and showed no beneficial effect at 18 months of corrected age.
